Pharmacology & Pharmacy
Vol.5 No.2(2014), Paper ID 42715, 10
pages
DOI:10.4236/pp.2014.52019
Safety, Tolerability, and Pharmacokinetics of E3030, a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist, in Healthy Japanese Male Subjects
Yutaka Takeuchi, Yuki Nishioka, Yasumi Kitahara, Setsuo Hasegawa, Akihiro Ohnishi
Clinical Development, Japan/Asia Clinical Research PCU, Eisai Co., Ltd., Tokyo, Japan
Japan Regulatory Affairs, Global Regulatory CFU, Eisai Co., Ltd., Tokyo, Japan
Clinical Development, Japan/Asia Clinical Research PCU, Eisai Co., Ltd., Tokyo, Japan
Sekino Clinical Pharmacology Clinic, Tokyo, Japan;Present address: Pharmaspur, Inc., Tokyo, Japan
Department of Laboratory Medicine, Daisan Hospital, Jikei University School of Medicine, Tokyo, Japan
Copyright © 2014 Yutaka Takeuchi, Yuki Nishioka, Yasumi Kitahara, Setsuo Hasegawa, Akihiro Ohnishi et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Y. Takeuchi, Y. Nishioka, Y. Kitahara, S. Hasegawa and A. Ohnishi, "Safety, Tolerability, and Pharmacokinetics of E3030, a Novel Peroxisome Proliferator-Activated Receptor
α/γ Dual Agonist, in Healthy Japanese Male Subjects,"
Pharmacology & Pharmacy, Vol. 5 No. 2, 2014, pp. 139-148. doi:
10.4236/pp.2014.52019.